Beam looks to accelerated approval for AATD base editing after promising update
Beam Therapeutics在取得积极进展后寻求AATD碱基编辑的加速批准

Beam Therapeutics has provided a much-awaited update on its therapy that uses a form of CRISPR called base editing to precisely fix a single genetic typo responsible for a rare genetic disease.
Beam Therapeutics发布了备受期待的最新进展：其疗法采用一种称为“碱基编辑”的CRISPR技术，可精确修复导致一种罕见遗传病的单个基因“错别字”。